



CritiTech, Inc. Announces Additions to the Board of Directors and the Scientific Advisory Board

August 24, 2010

Lawrence, Kansas- Sam Campbell, Chairman and President of CritiTech, Inc. announced today the addition of Dr. Francois Sauer, M.D., MBA to its Board of Directors and Dr. Michael Baltezor, Ph.D. to its Scientific Advisory Board. "We welcome the addition of these two very experienced and accomplished gentlemen to our team. I am confident that they will play an important role in the future success of CritiTech" said Campbell.

Dr. Sauer received his M.D. degree with honors from the University of Mexico, UNAM, his MBA from IPADE (Harvard Business School program in Mexico City), and a MS Systems Analysis from the Spanish-American University, Mexico City. Presently, Dr. Sauer is the CEO of Trans Am Group (TAG). TAG promotes importing and exporting between Mexico, Canada, and the United States with a focus on health services and logistics. Prior to that, he was the CEO of BCEC, a business incubator, and the CEO of Cerner International, maker of IT products for health industry applications with presence in Australia, Singapore, Malaysia, Saudi Arabia, and Europe. Dr. Sauer has served in numerous other business and professional leadership positions. He was a Founding member of the National Athenaeum of Arts, Letters, Sciences and Technology in Mexico and has published peer-reviewed articles in journals such as: British Medical Journal, Lancet, Military Medicine, and Nature Medicine. "Dr. Sauer will dynamically impact our board and expand the international presence of our company" Campbell said.

Dr. Michael Baltezor received his Ph. D. in Pharmaceutics and Pharmaceutical Chemistry from the University of Kansas in 1977. He has been involved in the development of pharmaceutical and medicinal products for over 30 years with Sandoz Pharmaceuticals, Marion Laboratories (and subsequent companies) and in the contract services business with Quintiles. He also served as the Vice President of R&D for CareFusion, Inc. Most recently, Dr. Baltezor became the Director of the Biotechnology Innovation and Optimization Center at the University of Kansas. His experience has included a spectrum of ethical and OTC drugs and devices including traditional oral solid and liquid dosage forms, topical products and injectable parenteral products. Dr. Baltezor's primary areas of expertise are in pharmaceutics, physical chemistry and analytical chemistry with a focus on novel drug delivery and the resolution of drug solubilization and stabilization. Dr. Charles Decedue, Chairman of CritiTech's Scientific Advisory Board, said "Dr. Baltezor is a great addition to CritiTech's Scientific Advisory Board. His vast experience in both large pharmaceutical companies and highly competitive contract research organizations will have a large impact on CritiTech's R&D efforts".

CritiTech provides critical drug delivery and development technology for the pharmaceutical industry. CritiTech produces fine-particle pharmaceuticals including nanoparticle pharmaceuticals using patented technologies developed at the University of Kansas. The processes use compressed carbon dioxide as the processing medium to produce residue-free and uniform drug microparticles and coatings.

The pharmaceutical industry has exhibited substantial interest in the processes that produce improved formulations using nanoparticulate drugs. CritiTech has used its proprietary technology to coat medicinal agents either on small particle drugs for improved drug delivery or as a thin film on implantable medical devices such as cardiac stents. CritiTech's first oncology drug, Nanotax®, for the treatment of ovarian cancer, is in Phase I human clinical trials. CritiTech plans to have its second oncology drug, Nanothecin™, for the treatment of colorectal cancer, in Phase I human trials early next year.

For additional information please contact:

Sam Campbell, Chairman/President: samcampbell@crititech.com

CritiTech, Inc.: www.crititech.com

1321 Wakarusa Dr. Suite 2102

Lawrence, KS 66049

p.785.841.7120